Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine in metastatic HER2-positive breast cancer patients.
Phase of Trial: Phase IV
Latest Information Update: 31 Aug 2015
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2015 New trial record
- 03 Jun 2014 Results in 5 patients presented at the 50th Annual Meeting of the American Society of Clinical Oncology.